G. Klingelschmitt

发表

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2010, The Lancet. Oncology.

Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

A. Traboulsee, L. Kappos, G. Comi, 2017, The New England journal of medicine.

Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies

D. Arnold, L. Kappos, A. Bar-Or, 2016 .

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

H. Groen, J. Milanowski, T. Ciuleanu, 2013, Lung cancer.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Federico Cappuzzo, Paul Delmar, Tudor Ciuleanu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.

F. Cappuzzo, W. Brugger, G. Klingelschmitt, 2013, Lung Cancer.

valuation of EGFR protein expression by immunohistochemistry sing H-score and the magnification rule : Re-analysis of the SATURN tudy

G. Klingelschmitt, ulien Mazièresa, Wolfram Bruggerb, 2013 .

Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.

S. Walzer, E. Juhász, G. Klingelschmitt, 2013, European journal of cancer.

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.

A. Haycox, G. Klingelschmitt, H. von Büdingen, 2021, Multiple Sclerosis and Related Disorders.

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

C. Ng, Keunchil Park, Yi-long Wu, 2012, Lung cancer.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

M. Ranson, I. Melezínek, G. Klingelschmitt, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

Jacqueline Palace, A. Traboulsee, K. Fujihara, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations

F. Cappuzzo, T. Mok, O. Spleiss, 2016 .

Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials

A. Traboulsee, B. Weinshenker, G. Klingelschmitt, 2020 .

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2010, The Lancet. Oncology.

9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

G. Giaccone, F. Cappuzzo, Keunchil Park, 2009 .